Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (178) 178
life sciences & biomedicine (157) 157
humans (143) 143
oncology (117) 117
female (109) 109
male (101) 101
middle aged (94) 94
aged (86) 86
adult (66) 66
physics (65) 65
lung cancer (56) 56
lung neoplasms - drug therapy (52) 52
biological and medical sciences (47) 47
medical sciences (46) 46
lung neoplasms - pathology (44) 44
aged, 80 and over (42) 42
carcinoma, non-small-cell lung - drug therapy (38) 38
mutation (36) 36
respiratory system (36) 36
cancer (35) 35
chemistry (31) 31
electricity (31) 31
tumors (30) 30
measuring (29) 29
testing (29) 29
treatment outcome (29) 29
carcinoma, non-small-cell lung - pathology (28) 28
chemotherapy (28) 28
performing operations (28) 28
transporting (28) 28
animals (27) 27
lung cancer, non-small cell (26) 26
analysis (25) 25
patients (25) 25
lung neoplasms - mortality (24) 24
metallurgy (24) 24
neoplasm staging (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
antineoplastic agents - therapeutic use (21) 21
carcinoma, non-small-cell lung - mortality (21) 21
care and treatment (21) 21
non-small cell lung cancer (21) 21
research (21) 21
human necessities (20) 20
lung neoplasms - genetics (20) 20
protein kinase inhibitors - therapeutic use (19) 19
tyrosine (19) 19
general tagging of cross-sectional technologies spanning over several sections of the ipc (18) 18
general tagging of new technological developments (18) 18
japan (18) 18
medicine & public health (18) 18
non-small cell lung carcinoma (18) 18
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (18) 18
genetic aspects (16) 16
investigating or analysing materials by determining theirchemical or physical properties (16) 16
pneumology (16) 16
retrospective studies (16) 16
tumor cells, cultured (16) 16
tumors of the respiratory system and mediastinum (16) 16
antineoplastic agents (15) 15
prognosis (15) 15
rats (15) 15
basic electric elements (14) 14
electric communication technique (14) 14
heating (14) 14
lung neoplasms - diagnosis (14) 14
optics (14) 14
blasting (13) 13
calculating (13) 13
computing (13) 13
counting (13) 13
epidermal growth factor (13) 13
hematology, oncology and palliative medicine (13) 13
lighting (13) 13
mechanical engineering (13) 13
oncology, experimental (13) 13
physical sciences (13) 13
protein-tyrosine kinase (13) 13
pulmonary/respiratory (13) 13
respiratory tract diseases (13) 13
survival rate (13) 13
testing static or dynamic balance of machines orstructures (13) 13
testing structures or apparatus not otherwise provided for (13) 13
weapons (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
cancer therapies (12) 12
clinical trials (12) 12
combustion engines (12) 12
disease-free survival (12) 12
epidermal growth factor receptors (12) 12
hot-gas or combustion-product engine plants (12) 12
multivariate analysis (12) 12
pharmacology. drug treatments (12) 12
pictorial communication, e.g. television (12) 12
receptor, epidermal growth factor - genetics (12) 12
research article (12) 12
technologies or applications for mitigation or adaptation againstclimate change (12) 12
adenocarcinoma - pathology (11) 11
climate change mitigation technologies related totransportation (11) 11
erbb receptors - genetics (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
by Hida, Toyoaki, MD and Nokihara, Hiroshi, MD and Kondo, Masashi, MD and Kim, Young Hak, MD and Azuma, Koichi, MD and Seto, Takashi, MD and Takiguchi, Yuichi, Prof and Nishio, Makoto, MD and Yoshioka, Hiroshige, MD and Imamura, Fumio, MD and Hotta, Katsuyuki, Prof and Watanabe, Satoshi, MD and Goto, Koichi, MD and Satouchi, Miyako, MD and Kozuki, Toshiyuki, MD and Shukuya, Takehito, MD and Nakagawa, Kazuhiko, Prof and Mitsudomi, Tetsuya, Prof and Yamamoto, Nobuyuki, Prof and Asakawa, Takashi, PhD and Asabe, Ryoichi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by Ramalingam, Suresh S and Vansteenkiste, Johan and Planchard, David and Cho, Byoung Chul and Gray, Jhanelle E and Ohe, Yuichiro and Zhou, Caicun and Reungwetwattana, Thanyanan and Cheng, Ying and Chewaskulyong, Busyamas and Shah, Riyaz and Cobo, Manuel and Lee, Ki Hyeong and Cheema, Parneet and Tiseo, Marcello and John, Thomas and Lin, Meng-Chih and Imamura, Fumio and Kurata, Takayasu and Todd, Alexander and Hodge, Rachel and Saggese, Matilde and Rukazenkov, Yuri and Soria, Jean-Charles and FLAURA Investigators
The New England journal of medicine, ISSN 0028-4793, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
by Goto, Koichi, Dr and Ohe, Yuichiro, MD and Shibata, Taro, MSc and Seto, Takashi, MD and Takahashi, Toshiaki, MD and Nakagawa, Kazuhiko, Prof and Tanaka, Hiroshi, MD and Takeda, Koji, MD and Nishio, Makoto, MD and Mori, Kiyoshi, MD and Satouchi, Miyako, MD and Hida, Toyoaki, MD and Yoshimura, Naruo, MD and Kozuki, Toshiyuki, MD and Imamura, Fumio, MD and Kiura, Katsuyuki, Prof and Okamoto, Hiroaki, MD and Sawa, Toshiyuki, MD and Tamura, Tomohide, MD and JCOG0605 investigators and JCOG0605 Investigators
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
by Hirashima, Tomonori and Satouchi, Miyako and Hida, Toyoaki and Nishio, Makoto and Kato, Terufumi and Sakai, Hiroshi and Imamura, Fumio and Kiura, Katsuyuki and Okamoto, Isamu and Kasahara, Kazuo and Uchida, Hirohiko and Vowler, Sarah L and Mitsudomi, Tetsuya
Cancer science, ISSN 1347-9032, 09/2019, Volume 110, Issue 9, pp. 2884 - 2893
EGFR mutation | non‐small‐cell lung cancer | tyrosine kinase inhibitor | acquired resistance | osimertinib | Life Sciences & Biomedicine | Oncology | Science & Technology | Japan - epidemiology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Diarrhea - epidemiology | Lung Neoplasms - pathology | Lung Diseases, Interstitial - chemically induced | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Paronychia - epidemiology | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Adult | Aniline Compounds - administration & dosage | Lung Diseases, Interstitial - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Paronychia - chemically induced | ErbB Receptors - antagonists & inhibitors | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Exanthema - epidemiology | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Progression-Free Survival | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Drug Resistance, Neoplasm - drug effects | Tyrosine | Medical research | Chemotherapy | Analysis | Medicine, Experimental | Development and progression | Respiratory tract diseases | Lung cancer, Non-small cell | Cancer | Epidermal growth factor receptors | Research funding | Lung cancer | Lung diseases | Clinical trials | Diarrhea | Non-small cell lung carcinoma | Cancer therapies | Studies | Epidermal growth factor | Platinum | Skin | Mutation | Safety | Protein-tyrosine kinase | Pharmaceuticals | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text High‐throughput screening in colorectal cancer tissue‐originated spheroids
by Kondo, Jumpei and Ekawa, Tomoya and Endo, Hiroko and Yamazaki, Kanami and Tanaka, Norio and Kukita, Yoji and Okuyama, Hiroaki and Okami, Jiro and Imamura, Fumio and Ohue, Masayuki and Kato, Kikuya and Nomura, Taisei and Kohara, Arihiro and Mori, Seiichi and Dan, Shingo and Inoue, Masahiro
Cancer science, ISSN 1347-9032, 01/2019, Volume 110, Issue 1, pp. 345 - 355
cancer | 3D culture | high throughput screening | heterogeneity | organoid | Life Sciences & Biomedicine | Oncology | Science & Technology | Cell Survival - drug effects | Drug Screening Assays, Antitumor - methods | Organoids - pathology | Colorectal Neoplasms - genetics | Humans | Spheroids, Cellular - metabolism | Spheroids, Cellular - pathology | Cell Survival - genetics | Mice, SCID | Xenograft Model Antitumor Assays - methods | Whole Exome Sequencing | Animals | Organoids - metabolism | Organoids - drug effects | Cell Line, Tumor | Mice, Inbred NOD | Antineoplastic Agents - pharmacology | Spheroids, Cellular - drug effects | Colorectal Neoplasms - pathology | High-Throughput Screening Assays - methods | Drugs | Research & development--R&D | Colorectal carcinoma | Innovations | Genomes | Drug screening | Drug development | Patients | Experiments | Spheroids | Organoids | Precision medicine | Morphology | Xenografts | Life sciences | Genetic testing | Deoxyribonucleic acid--DNA | Cancer | Tumors | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: A case control study
by Maeda, Jun and Higashiyama, Masahiko and Imaizumi, Akira and Nakayama, Tomio and Yamamoto, Hiroshi and Daimon, Takashi and Yamakado, Minoru and Imamura, Fumio and Kodama, Ken
BMC cancer, ISSN 1471-2407, 12/2010, Volume 10, Issue 1, pp. 690 - 690
Life Sciences & Biomedicine | Oncology | Science & Technology | Metabolomics | Predictive Value of Tests | Amino Acids - blood | Prognosis | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Chromatography, High Pressure Liquid | Mass Screening - methods | Case-Control Studies | Young Adult | Spectrometry, Mass, Electrospray Ionization | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Reproducibility of Results | Japan | Logistic Models | Biomarkers, Tumor - blood | Carcinoma, Non-Small-Cell Lung - blood | ROC Curve | Aged | Lung Neoplasms - blood | Lung Neoplasms - diagnosis | Analysis | Amino acids | Diagnosis | Research | Lung cancer, Non-small cell | Methods | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
by Kodama, Ken, MD and Higashiyama, Masahiko, MD and Okami, Jiro, MD and Tokunaga, Toshiteru, MD and Imamura, Fumio, MD and Nakayama, Tomio, MD and Inoue, Atsuo, MD and Kuriyama, Keiko, MD
The Annals of thoracic surgery, ISSN 0003-4975, 2016, Volume 101, Issue 2, pp. 504 - 511
Surgery | Cardiothoracic Surgery | Cardiac & Cardiovascular Systems | Respiratory System | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Japan - epidemiology | Carcinoma, Non-Small-Cell Lung - surgery | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Tomography, X-Ray Computed | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - diagnosis | Carcinoma, Non-Small-Cell Lung - mortality | Propensity Score | Pneumonectomy - methods | Time Factors | Female | Lung Neoplasms - surgery | Aged | Lung Neoplasms - diagnosis | Neoplasm Staging | Lung cancer, Non-small cell | Lung cancer, Small cell | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
by Uchida, Junji and Imamura, Fumio and Kukita, Yoji and Oba, Shigeyuki and Kumagai, Toru and Nishino, Kazumi and Inoue, Takako and Kimura, Madoka and Kato, Kikuya
Cancer science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 353 - 358
lung cancer | Carcinoembryonic antigen | epidermal growth factor receptor tyrosine kinase inhibitor | massively parallel DNA sequencer | circulating tumor DNA | Epidermal growth factor receptor tyrosine kinase inhibitor | Massively parallel DNA sequencer | Lung cancer | Circulating tumor DNA | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Mutation, Missense | Biomarkers, Tumor - blood | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Tyrosine | Development and progression | Epidermal growth factor | Multiprocessing | Analysis | DNA | Phenols | Genetic research | Genetic aspects | Nucleotide sequencing | CEA (Oncology) | Cancer | DNA sequencing | Plasma | Disease | Laboratories | Cytotoxicity | Gene deletion | Kinases | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Subpopulations | Nucleotide sequence | Epidermal growth factor receptors | Invasiveness | Patients | Studies | Genotyping | Biopsy | Mutation | Genetic testing | Cytotoxic agents | Tumors | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
by Riichiroh Maruyama and Yutaka Nishiwaki and Tomohide Tamura and Nobuyuki Yamamoto and Masahiro Tsuboi and Kazuhiko Nakagawa and Tetsu Shinkai and Shunichi Negoro and Fumio Imamura and Kenji Eguchi and Koji Takeda and Akira Inoue and Keisuke Tomii and Masao Harada and Noriyuki Masuda and Haiyi Jiang and Yohji Itoh and Yukito Ichinose and Nagahiro Saijo and Masahiro Fukuoka
Journal of clinical oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 26, pp. 4244 - 4252
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Proportional Hazards Models | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Taxoids - therapeutic use | Quinazolines - therapeutic use | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study
by Morimoto, Akira and Shioda, Yoko and Imamura, Toshihiko and Kudo, Kazuko and Kawaguchi, Hiroshi and Sakashita, Kazuo and Yasui, Masahiro and Koga, Yuhki and Kobayashi, Ryoji and Ishii, Eiichi and Fujimoto, Junichiro and Horibe, Keizo and Bessho, Fumio and Tsunematsu, Yukiko and Imashuku, Shinsaku
International journal of hematology, ISSN 0925-5710, 7/2016, Volume 104, Issue 1, pp. 99 - 109
Clinical trials | Oncology | Chemotherapy | Medicine & Public Health | Hematology | Langerhans cell histiocytosis | Life Sciences & Biomedicine | Science & Technology | Histiocytosis, Langerhans-Cell - mortality | Prednisolone - administration & dosage | Humans | Child, Preschool | Clinical Protocols - standards | Treatment Outcome | Cytarabine - administration & dosage | Multiple Organ Failure | Disease-Free Survival | Drug Therapy, Combination - methods | Time Factors | Adolescent | Cyclosporine - administration & dosage | Vincristine - administration & dosage | Remission Induction - methods | Child | Histiocytosis, Langerhans-Cell - drug therapy | Care and treatment | Corticosteroids | Histiocytosis | Patient outcomes | Prednisolone | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights